Asthma Competitive Landscape Report 2023 (Updated)

Asthma Competitive Landscape Report 2023 (Updated)

DelveInsight’s, “Asthma Competitive Landscape 2023” report provides comprehensive insights about 110+ Asthma companies and 125+ drugs in Asthma Competitive landscape. It covers the Asthma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Asthma pipeline products in this space.

 

Key Takeaways from the Asthma Competitive Landscape Report

  • DelveInsight’s Asthma report depicts a robust space with 110+ Asthma companies working to develop 125+ pipeline therapies for Asthma treatment.
  • The leading Asthma Companies working in the market include Areteia Therapeutics, Celltrion, GlaxoSmithKline, Connect Biopharma, Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Chia Tai Tianqing Pharmaceutical Group, Aldeyra Therapeutics, Inc., Trio Medicines, AstraZeneca, Janssen Research & Development, Tetherex Pharmaceuticals Corporation, Palobiofarma SL, Sanofi, RAPT Therapeutics, Kashiv BioSciences, Archivel Farma, TFF Pharmaceuticals, Evelo Biosciences Inc., Landos Biopharma, Adial Pharmaceuticals, Holth Therapeutics, Lanier Biotherapeutics, Omega Therapeutics, Transpire Bio, DNARx, Argenx, MyMD Pharmaceuticals, Ventyx Biosciences, Kither, Enterprise Therapeutics, and others.
  • Promising Asthma therapies in the various stages of development include DUPIXENT®, Tezepelumab, MEDI9929, Revamilast, Benralizumab, AZD7594, GSK3511294 (Depemokimab), ONO-6950, Montelukast, and others.
  • December 2023: Sanofi announced a study of Phase 4 clinical trials for Dupilumab. A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma.
  • December 2023: AstraZeneca announced a study of phase 4 clinical trials for Tezepelumab. To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.

 

Request a sample and discover the recent advances in Asthma Drugs @ Asthma Competitive Landscape Report

 

The Asthma report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the Asthma report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

 

Asthma Overview

Asthma is a chronic disease that affects the airways. Asthma is characterized by inflammation and spasm of the airways. The airways are tubes that carry air in and out of the lungs. If a person has asthma, the inside walls of the airways become sore and swollen. The air passages in the lungs become narrow due to inflammation and tightening of the muscles around the small airways.

 

Find out more about Asthma Analytical Perspective: In-depth Commercial Assessment @ Asthma Collaboration Analysis by Companies

 

Asthma Companies and Therapies

  • Regeneron Pharmaceuticals: Dupixent
  • Novartis Pharmaceuticals: QVM149
  • Areteia Therapeutics: Dexpramipexole
  • Connect Biopharma: CBP-201
  • United BioPharma: UB-221
  • 4D Pharma Plc.: MRx-4DP0004

 

Asthma Competitive Landscape: Analytical Perspectives

The Asthma competitive landscape report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

 

Asthma Report Assessment

  • Company Analysis
  • Asthma Therapeutic Assessment
  • Asthma Pipeline Assessment
  • Inactive Asthma drugs assessment
  • Asthma Unmet Needs

 

Learn more about the emerging Asthma Competitive Landscape @ Asthma Market Drivers and Barriers, Unmet Needs

 

Scope of the Asthma Competitive Landscape Report

  • Coverage- Global
  • Asthma Companies- Areteia Therapeutics, Celltrion, GlaxoSmithKline, Connect Biopharma, Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Chia Tai Tianqing Pharmaceutical Group, Aldeyra Therapeutics, Inc., Trio Medicines, AstraZeneca, Janssen Research & Development, Tetherex Pharmaceuticals Corporation, Palobiofarma SL, Sanofi, RAPT Therapeutics, Kashiv BioSciences, Archivel Farma, TFF Pharmaceuticals, Evelo Biosciences Inc., Landos Biopharma, Adial Pharmaceuticals, Holth Therapeutics, Lanier Biotherapeutics, Omega Therapeutics, Transpire Bio, DNARx, Argenx, MyMD Pharmaceuticals, Ventyx Biosciences, Kither, Enterprise Therapeutics, and others.
  • Asthma therapies- DUPIXENT®, Tezepelumab, MEDI9929, Revamilast, Benralizumab, AZD7594, GSK3511294 (Depemokimab), ONO-6950, Montelukast, and others.
  • Asthma Therapeutics Assessment- Product Type, Stage and Product Type, Route of Administration, Stage and Route of Administration, Molecule Type, Stage and Molecule Type

 

Dive deep into rich insights for new drugs for Asthma Product Developmental Activities, Visit @ Asthma Research and Development Activities

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Asthma: Overview
  4. Asthma-Analytical Perspective: In-depth Commercial Assessment
  5. Asthma Competitive Landscape
  6. Asthma Therapeutic Assessment
  7. Asthma: Company and Product Profiles (Marketed Therapies)
  8. Regeneron Pharmaceuticals
  9. Dupixent
  10. Asthma: Company and Product Profiles (Pipeline Therapies)
  11. Late Stage Products (Phase III)
  12. Areteia Therapeutics
  13. Dexpramipexole
  14. Drug profiles in the detailed report…..
  15. Mid Stage Products (Phase II)
  16. Connect Biopharma
  17. CBP-201
  18. Drug profiles in the detailed report…..
  19. Early Stage Products (Phase I)
  20. United BioPharma
  21. UB-221
  22. Drug profiles in the detailed report…..
  23. Preclinical and Discovery Stage Products
  24. Olatec Therapeutics
  25. Dapansutrile
  26. Drug profiles in the detailed report…..
  27. Inactive Products
  28. Asthma Unmet needs
  29. Asthma Market drivers and barriers
  30. Appendix

 

For further information on the Asthma Report @ Asthma Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services